

medicines  
patent  
pool

# How can voluntary licensing improve access to innovative cancer medicines in low- and middle-income countries?


Giulia Segafredo, MPP

[MEDICINESPATENTPOOL.ORG](https://www.medicinespatentpool.org)

- What is voluntary licensing? Brief introduction to MPP
- What did we achieve so far?
- MPP priorities (in cancer)
- How can we work together?

# What is MPP and how does MPP model work?

A UN-backed public health organization operating since 2010. MPP aims to improve access to medicines and health technologies, particularly in LMICs, and facilitate further innovation through non-exclusive voluntary licensing.



# What is MPP's scope of work?

**Created in 2010**  
as first voluntary  
licensing and patent  
pooling mechanism  
in public health



**To increase access to new treatments for HIV** through licensing of patented medicines and facilitate innovation e.g. new combinations or paediatric formulations

**In 2015,**  
**expanded**  
mandate to  
Hepatitis C and  
Tuberculosis



**In 2018** decision to expand to **other patented essential medicines** and those with strong potential for future inclusion => **non-communicable diseases including cancer**



**In 2020,**  
expanded to health  
technologies relevant  
for **COVID-19**



**In 2021** inclusion of **biotherapeutics** that are either on the WHO EML or have strong potential for future inclusion






**In 2021,** expansion to **technology transfer** with an initial focus on COVID-19 vaccines and pandemic preparedness






 lopinavir ritonavir (adults) lopinavir ritonavir (paediatrics)	 nevirapine (non-assert)	 atazanavir	 bicitegravir cobicistat elvitegravir emtricitabine tenofovir alafenamide tenofovir disoproxil	 darunavir (paediatric; non-assert)	 raltegravir (paediatric)	 darunavir related	 abacavir (paediatrics) cabotegravir long-acting (for HIV PrEP) dolutegravir (paediatrics) dolutegravir (adults)
--	---	---	---	---	--	--	--

**HIV**

 glecaprevir/pi brentasvir	 daclastavir	 ravidasvir
---	--	--


**VIRAL HEPATITIS**

 mdc-STM (malaria LAI)	 solid drug nanoparticles technology (disease agnostic) ETFD LAI (TB, malaria, HCV)	 abacavir (paediatrics) cabotegravir long-acting (for HIV PrEP) dolutegravir (paediatrics) dolutegravir (adults)	 TLD LAI (HIV)
---	---	--	--

**LONG-ACTING THERAPEUTICS**

  
 nilotinib  
**CANCER**

  
 sutezolid  
**TUBERCULOSIS**


 molnupiravir	 nirmatrelvir	 ensitrelvir fumaric acid	 rapid diagnostic testing (RDT) technology
--	---	---	--

**COVID-19**

  
 heat-stable carbetocin  
**MATERNAL HEALTH**

# MPP's network of generic manufacturers and product developers are in 14 countries ensuring the importance of local production

55 generic  
manufacturers  
and product  
developers



<b>Bangladesh</b> Incepta	Aurisco Biochem BrightGene Desano Fosun	Jiuzhou Huahai Langhua Lonzeal	<b>Dominican Republic</b> Magnachem	Arene Aurobindo BDR Biocon Biophore Cadila	Cipla Divi's Dr Reddy's Emcure Glenmark Granules	Hetero Laurus Lupin Macleods Mangalam Micro Labs	MSN Natco SMS Pharma Strides Sun Torrent	USV Viatrix Zydus Cadila	<b>Indonesia</b> Kimia Farma	<b>Kenya</b> UCL	<b>Pakistan</b> Remington	<b>South Africa</b> Adcock Ingram Biotech CPT	<b>South Korea</b> Celltrion Dongbang	<b>Vietnam</b> Stella
<b>China</b> Apeloa			<b>India</b> Amneal						<b>Jordan</b>	<b>Mexico</b> Neolpharma	<b>Serbia</b> FHI Zdravlje		<b>Ukraine</b> Darnitsa	<b>Product developers</b> TB Alliance Gates MRI



## Our footprint – MPP’s impact

Data based on methodology described in peer-reviewed paper: Morin et al “The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study” **The Lancet Public Health**, 2021

**34.69  
Bn**

doses of  
treatment  
supplied  
(2010 - 2022)



**USD  
1.5 Bn**

dollars saved  
through  
MPP’s licences  
(2010 - 2022)



By 2030

**170,000**

projected  
deaths  
averted



**148**

countries have  
benefited from  
access to MPP’s  
products



**93.89  
million**

patient years of  
treatment  
through MPP’s  
generic partners  
(2010 - 2021)



By 2030

**USD  
3.8 Bn**

projected  
savings



# MPP priority medicines in the oncology space

PRIORITY AND WATCHLIST MEDICINES FOR IN-LICENSING  
BY THE MEDICINES PATENT POOL

JANUARY 2024



VIRAL  
HEPATITIS



## ONCOLOGY

LUNG CANCER	BREAST CANCER	CHRONIC LYMPHOCYTIC LEUKAEMIA	PROSTATE CANCER	MULTIPLE CANCER INDICATIONS
<p><b>aumolertinib</b> <i>Revolution Medicines</i></p> <p><b>osimertinib</b> <i>Astrazeneca</i></p> <p><b>adagrasib</b> <i>Mirati</i></p> <p><b>lazertinib</b> <i>Janssen</i></p> <p><b>sotorasib</b> <i>Amgen</i></p>	<p><b>abemaciclib</b> <i>Eli Lilly</i></p> <p><b>ribociclib</b> <i>Novartis</i></p> <p><b>trastuzumab SQ</b> <i>Roche</i></p>	<p><b>ibrutinib</b> <i>Janssen</i></p> <p><b>zanubrutinib</b> <i>Beigene</i></p>	<p><b>apalutamide</b> <i>Janssen</i></p> <p><b>darolutamide</b> <i>Bayer</i></p>	<p>immune checkpoint inhibitors <i>Multiple patent holders</i></p> <p>including <b>pembrolizumab</b> <i>MSD</i></p> <p><b>oral paclitaxel / encequidar</b> <i>Athenex</i></p>

sotorasib *Amgen*

PRIORITY LIST

WATCHLIST



# Access to MPP-licensed medicines

## Patent and licence information tools

- To support procurement agencies, national programmes, and treatment advocates
- Fully public quarterly-updated country-by-country information

**MedsPaL**  
THE MEDICINES PATENTS AND LICENCES DATABASE



[www.medspal.org](http://www.medspal.org)

**VaxPaL**  
COVID-19 VACCINES PATENT LANDSCAPE

[www.vaxpal.org](http://www.vaxpal.org)

**LAPaL**  
THE LONG-ACTING THERAPEUTICS  
PATENTS AND LICENCES DATABASE

<https://lapal.medicinespatentpool.org>



## Access to Medicines Tracker – Interactive Table

Key: ■ HIV ■ Hepatitis C ■ Tuberculosis

Filter table rows by product  Filter

PRODUCTS	COMPANIES DEVELOPING THE PRODUCT	PENDING APPROVAL			READY TO SUPPLY			COUNTRIES WHERE		
		WHO-PQ*	USFDA**	WHO-PQ* APPROVED	USFDA** APPROVED	ERP*** APPROVED	PRODUCT IS FILED	PRODUCT IS APPROVED	PRODUCT IS SUPPLIED	
DTG 50mg	12			Cipla DISEA <sup>TM</sup>	 Cipla		Benin, Bolivia (Plurinational)	Anguilla, Antigua and Barbuda,	Afghanistan, Albania, Angola,	

More at: <https://medicinespatentpool.org/what-we-do/medspal>  
<https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker>

# Access to cancer medicines and the strategic importance of multi-stakeholder partnerships

MPP collaboration and interactions in the oncology space



The selection and use of essential medicines  
2023

Executive summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines

promising but not yet sufficiently mature. However, the Committee considered that cyclin-dependent kinase 4/6 inhibitors, daratumumab, osimertinib, PD 1/PD-L1 immune checkpoint inhibitors and zanubrutinib all had potential for future inclusion and recommended the Medicines Patent Pool explore the application of its licensing model to these medicines.



Currently exploring:



#BetterMeds4Kids series:  
Join us for GAP-f's quarterly webinar on paediatric optimization to close the paediatric medicines gap

**Prioritizing the most needed paediatric formulations: a focus on NTDs and childhood cancer**


Hosted by GAP-f's Prioritization Working Group  
Thursday March 21, 2024  
1330 CET / 0830 EST / 1800 IST (90 minutes)

Register Here:  
<https://bit.ly/48leBMH>




# MPP-Inspire2Live – how can we work together?

- Informing priorities
  - MPP seeks to monitor innovation in terms of new MoA and new formulations (e.g. heat stable and/or oral formulations) => additional candidates you consider relevant?
- Create an enabling environment for in-licensing
  - Patients' voices, especially coming from LMICs
  - Collaboration on advocacy activities?



medicines  
patent  
pool

Thank you



[MEDICINESPATENTPOOL.ORG](https://www.medicinespatentpool.org)

 [YOUTUBE.COM/USER/MEDICINESPATENTPOOL](https://www.youtube.com/user/medicinespatentpool)

 [WWW.LINKEDIN.COM/COMPANY/MEDICINES-PATENT-POOL/](https://www.linkedin.com/company/medicines-patent-pool/)

 [YOUTUBE.COM/USER/MEDICINESPATENTPOOL](https://www.youtube.com/user/medicinespatentpool)